[10] Patent/Publication Number: WO2004113345A1

[43] Publication Date: Dec. 29, 2004

[54] FUSED PYRROLE COMPOUND AND MEDICINAL USE THEREOF

[72, 75] **Inventor(s)**:

NAKAMURA; Takeshi, c/o Central Pharmaceutical Research Institute of Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki-shi, Osaka 5691125 JP JP JP

TAKAGI; Masaki, c/o Central Pharmaceutical Research Institute of Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki-shi, Osaka 5691125 JP JP

KIGUCHI; Toshihiro, c/o Central Pharmaceutical Research Institute of Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki-shi, Osaka 5691125 JP JP JP

IKENOGAMI; Taku, c/o Central Pharmaceutical Research Institute of Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki-shi, Osaka 5691125 JP JP JP

UEDA; Nobuhisa, c/o Central Pharmaceutical Research Institute of Japan Tobacco Inc., 1-1, Murasaki-cho, Takatsuki-shi, Osaka 5691125 JP JP JP

- [71] Assignee/Applicant:

 JAPAN TOBACCO INC., 2-1, Toranomon 2-chome, Minato-ku, Tokyo 1058422 JP JP JP
- [30] **Priority:**JP Jun. 20, 2003 2003-177213
- [21] Application Number: JP04008917 JP
- [22] Application Date: Jun. 18, 2004
- [51] Int. Cl.⁷: C07D49504
- [56] References Cited:

U.S. PATENT DOCUMENTS

03037864 /PCIT WO (Y) [0]

FOREIGN PATENT DOCUMENTS

2001302546 /PCIT JP (Y) [0] 2001131181 /PCIT JP (Y) [0] 0220530 /REFS WO (Y) [0]

Attorney, Agent, or Firm - TAKASHIMA, Hajime

[57] ABSTRACT

A fused pyrrole compound represented by the general formula (1): (1) (wherein the symbols have the same meanings as in the description), a prodrug thereof, or a pharmaceutically acceptable salt of either. The compound (1), prodrug, and salt are useful as a therapeutic agent for diabetes which has HLGPa inhibitory activity.

DETAILS	
NotAvailable	
CLAIMS (ENGLISH)	
NotAvailable	
CLAIMS (FRENCH)	
NotAvailable	
CLAIMS (GERMAN)	
NotAvailable	

MicroPatent HTML record

NotAvailable

Page 2 of 2